Triple
T10292323
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | ENSEMBLE trial |
E241392
|
entity |
| Predicate | developerOfInvestigationalProduct |
P40576
|
FINISHED |
| Object | Ad26.COV2.S |
E241393
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ad26.COV2.S | Statement: [ENSEMBLE trial, developerOfInvestigationalProduct, Ad26.COV2.S]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ad26.COV2.S Context triple: [ENSEMBLE trial, developerOfInvestigationalProduct, Ad26.COV2.S]
-
A.
Ad26.COV2.S
chosen
Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
-
B.
human adenovirus serotype 26 (Ad26)
Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
-
C.
SARS-CoV-2
SARS-CoV-2 is the novel coronavirus responsible for the global outbreak of the respiratory disease COVID-19.
-
D.
BNT162b2
BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
-
E.
Human mastadenovirus D
Human mastadenovirus D is a species of human adenoviruses that includes multiple serotypes, some of which are used as viral vectors in vaccine development and gene therapy.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: developerOfInvestigationalProduct Context triple: [ENSEMBLE trial, developerOfInvestigationalProduct, Ad26.COV2.S]
-
A.
coPrincipalInvestigator
Indicates that an entity serves jointly with another as a principal investigator on the same research project or grant.
-
B.
chiefScientist
Indicates that one entity serves as the primary or lead scientist for another entity, typically holding top scientific authority or responsibility.
-
C.
developerOfWork
Indicates that one entity is the creator or producer responsible for making or developing a particular work.
-
D.
developmentLedBy
chosen
Indicates that the development of something is directed, managed, or overseen by a particular agent or entity.
-
E.
overseesDevelopmentOf
Indicates that one entity has responsibility for supervising, managing, or directing the development process of another entity.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d7500fdd1c81909395469afb346f8b |
completed | April 9, 2026, 7:06 a.m. |
| PD | Predicate disambiguation | batch_69d4d1f35e548190be3b4d92d65d2d20 |
completed | April 7, 2026, 9:44 a.m. |
Created at: April 6, 2026, 11:42 a.m.